文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症呼吸衰竭与机械通气

美国重症监护病房生命支持使用与结局趋势(2014-2023)

Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
PubMed 文献 · JAMA · 2025-01-01
一句话结论美国ICU十年数据显示:疫情期调整后住院死亡率升高后回落至基线,机械通气使用减少而血管升压药使用增加(7.2%升至21.6%)。

该回顾性队列研究基于美国54个持续贡献数据的健康系统(Epic Cosmos数据库),纳入2014-2023年因任何原因入住ICU的成人患者3,453,687例,旨在描述新冠疫情前、中、后美国重症监护的流行病学。主要结局为住院死亡率(未调整及调整人口学、合并症、病情严重度)、ICU住院时长及生命支持干预(机械通气、血管升压药)。结果显示总体住院死亡率为10.9%,疫情期调整后住院死亡率在新冠阴性(aOR 1.3,95%CI 1.2-1.3)和阳性(aOR 4.3,95%CI 3.8-4.8)患者中均升高,至2022年中回落至基线;ICU中位住院时长2.1天,疫情期新冠阳性患者较阴性患者延长2.0天(95%CI 2.0-2.1)。有创机械通气率疫情前23.2%、疫情期25.8%、之后降至22.0%;血管升压药使用从7.2%升至21.6%。

要点

  • 疫情期调整后住院死亡率升高:新冠阴性患者aOR 1.3(95%CI 1.2-1.3),新冠阳性患者aOR 4.3(95%CI 3.8-4.8),至2022年中回落至基线。
  • ICU中位住院时长2.1天,疫情期新冠阳性患者较阴性患者延长2.0天(95%CI 2.0-2.1)。
  • 有创机械通气率疫情前23.2%、疫情期25.8%、之后降至22.0%(低于疫情前基线)。
  • 血管升压药使用从7.2%升至21.6%的ICU住院。
  • 总体住院死亡率为10.9%,中位年龄65岁(IQR 53-75),男性55.3%。

适用人群与场景

  • 美国54个持续贡献数据的健康系统(Epic Cosmos数据库)中2014-2023年因任何原因入住ICU的成人患者,共3,453,687例ICU住院。

研究设计与关键结果

  • 研究类型为回顾性队列研究,样本量3,453,687例ICU住院,数据来自美国54个健康系统,人群为2014-2023年因任何原因入住ICU的成人患者。
  • 总体住院死亡率为10.9%;中位年龄65岁(IQR 53-75),男性55.3%,黑人17.3%,西班牙裔或拉丁裔6.1%。
  • 调整后住院死亡率在疫情期升高:新冠阴性患者aOR 1.3(95%CI 1.2-1.3),新冠阳性患者aOR 4.3(95%CI 3.8-4.8),至2022年中回落至基线。
  • ICU中位住院时长2.1天(IQR 1.1-4.2),疫情期新冠阳性患者较新冠阴性患者延长2.0天(95%CI 2.0-2.1)。
  • 有创机械通气率:疫情前23.2%(95%CI 23.1%-23.2%),疫情期25.8%(95%CI 25.8%-25.9%),之后降至22.0%(95%CI 21.9%-22.2%)。
  • 血管升压药使用从7.2%升至21.6%的ICU住院。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究显示疫情期调整后住院死亡率升高后回落至基线,机械通气使用较疫情前减少,而血管升压药使用增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Nationwide data are unavailable regarding changes in intensive care unit (ICU) outcomes and use of life support over the past 10 years, limiting understanding of practice changes.

OBJECTIVE: To portray the epidemiology of US critical care before, during, and after the COVID-19 pandemic.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of adult patients admitted to an ICU for any reason, using data from the 54 US health systems continuously contributing to the Epic Cosmos database from 2014-2023.

EXPOSURES: Patient demographics, COVID-19 status, and pandemic era.

MAIN OUTCOMES AND MEASURES: In-hospital mortality unadjusted and adjusted for patient demographics, comorbidities, and illness severity; ICU length of stay; and receipt of life-support interventions, including mechanical ventilation and vasopressor medications.

RESULTS: Of 3 453 687 admissions including ICU care, median age was 65 (IQR, 53-75) years. Patients were 55.3% male; 17.3% Black and 6.1% Hispanic or Latino; and overall in-hospital mortality was 10.9%. The adjusted in-hospital mortality was elevated during the pandemic in COVID-negative (adjusted odds ratio [aOR], 1.3 [95% CI, 1.2-1.3]) and COVID-positive (aOR, 4.3 [95% CI, 3.8-4.8]) patients and returned to baseline by mid-2022. The median ICU length of stay was 2.1 (IQR, 1.1-4.2) days, with increases during the pandemic among COVID-positive patients (difference for COVID-positive vs COVID-negative patients, 2.0 days [95% CI, 2.0-2.1]). Rates of invasive mechanical ventilation were 23.2% (95% CI, 23.1%-23.2%) before the pandemic, increased to 25.8% (95% CI, 25.8%-25.9%) during the pandemic, and declined below prepandemic baseline thereafter (22.0% [95% CI, 21.9%-22.2%]). The use of vasopressors increased from 7.2% to 21.6% of ICU stays.

CONCLUSIONS AND RELEVANCE: Pandemic-era increases in length of stay and adjusted in-hospital mortality among US ICU patients returned to recent historical baselines. Fewer patients are now receiving mechanical ventilation than prior to the pandemic, while more patients are administered vasopressor medications.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Moin EE, Seewald NJ, Halpern SD, et al. Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units. JAMA. 2025. PMID: 40227733. doi:10.1001/jama.2025.2163

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。